Does Hydroxychloroquine Work? New COVID-19 Evidence Accelerator Report Uses RWD to Determine Patient Outcomes

April 30, 2021

The COVID-19 Evidence Accelerator has published a new report in PLOS One. The manuscript examines how hydroxychloroquine and azithromycin affect patient outcomes using real world data (RWD). The researchers used electronic health data along with other data sources to explore mortality in more than 20,000 hospitalized COVID-19 patients.

“Ultimately, this first parallel analysis project helped lay the methodological and logistical groundwork for future collaborations using different RWD sources to generate rapid insights on COVID-19, helping advance the understanding of the disease and its interventions.” According to the study authors, “Neither hydroxychloroquine nor azithromycin, alone or in combination, were significantly associated with time to mortality among hospitalized COVID-19 patients.” Read more here.

(Source: Aetion, 4/1/21)

Share This Story!